Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
06:00pm, Friday, 30'th Dec 2022
Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business
Roche (RHHBY) Actemra Gets FDA Nod for Adults With COVID-19
10:33am, Thursday, 22'nd Dec 2022
Roche (RHHBY) obtains FDA approval for Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients. The drug was earlier granted an EUA.
Roche gets full FDA approval for COVID-19 treatment
09:49am, Thursday, 22'nd Dec 2022
Roche Holding AG ROG, -0.50% said late Wednesday that the Food and Drug Administration formally approved its monoclonal antibody for adults who have been hospitalized with severe COVID-19. Actemra rec
Roche's phase 3 data show Lymphoma treatment can reduce disease risks
02:24am, Monday, 12'th Dec 2022
Roche Holding AG presented new data from a Phase 3 study showing that its Polivy antibody-drug can significantly reduce the risk of disease deterioration or death for people with untreated diffuse lar
Roche names new CEO with Schwan set to become chairman
01:32am, Monday, 12'th Dec 2022
Roche has appointed Thomas Schinecker as the new group chief executive, the company said on Monday, replacing Severin Schwan who the pharmaceuticals giant has nominated to be its next chairman.
What's Driving Roche Stock?
09:00am, Thursday, 08'th Dec 2022
Looking at the longer term, Roche stock is up 27% from levels seen in late 2018, compared to around 65% returns for the S&P500 index.
Ferrero Roche owner agrees to buy Blue Bunny ice cream maker Wells Enterprises
04:51am, Thursday, 08'th Dec 2022
The Ferrero Group, the Italian confectionery group, said it has agreed to buy Wells Enterprises, the world's largest family owned and managed ice cream company, for an undisclosed sum. Iowa-based Wel
Roche: Another Key Fail.
04:37pm, Thursday, 17'th Nov 2022
Roche fails Alzheimer's treatment and consequently the stock declined. In numbers, we were estimating a 25% chance to reach $10 billion in sales (equal to 2% of the company's net present value).
Roche gets FDA Emergency Use Authorization for Monkeypox virus test
01:58am, Wednesday, 16'th Nov 2022
By Pierre Bertrand
Roche Alzheimer's failure good news for rivals, analysts suggest
07:51am, Tuesday, 15'th Nov 2022
Analysts were busy chopping back forecasts for Swiss group Roche going forward after what was described by one as the 'unequivocal failure' of gantenerumab, its treatment for Alzheimer's. Shares in Bi
Roche's Alzheimer drug fails, Newman's Own Foundation CEO retires, Dolly Parton receives $100M award
10:48am, Monday, 14'th Nov 2022
Yahoo Finance's Julie Hyman breaks down leading business stories including news that Roche's potential Alzheimer's drug has failed, the Newman's Own Foundation CEO plans to retire amid a lawsuit, and
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others
09:17am, Monday, 14'th Nov 2022
Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled. The post Roche's Alzheimer's Drug Fails In Phase 3; Here's The
Roche Sinks as Alzheimer's Drug Disappoints. Biogen is Gaining.
07:19am, Monday, 14'th Nov 2022
The Swiss pharma company said the drug failed to slow patients' clinical decline, in contrast to positive results from Biogen earlier this year.
MorphoSys shares plunge after partner Roche says Alzheimer's drug trials didn't meet goals
05:22am, Monday, 14'th Nov 2022
German-listed shares of MorphoSys MOR, -31.96% MOR, +2.44% lost a third of their value on Monday after its partner Roche said an Alzheimer drug trial failed. Roche ROG, -3.76% slumped 4% in Zurich as
Roche says Phase 3 studies for Alzheimer's drug failed to meet primary endpoints
02:13am, Monday, 14'th Nov 2022
Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of early Alzheimer's disease, failed to meet its primary endpoints.
